Preparation and in-vitro evaluation of PU- PCL films containing doxorubicin and ezetimibe on the prostate cancer cell line PC3

One of the most potentially hazardous diseases, prostate cancer has a high morbidity and mortality rate. Polymeric matrix drug-eluting implants have become widely employed, and modeling their behavior is becoming more and more prominent. It is always difficult to achieve effective drug delivery and release of it into specific tumor sites. One of the most significant purposes of this investigation, is the enhancement of the anticancer effects of prostate cancer treatment by co-delivering anticancer multi-drugs with PU-PCL films. The films were recognized utilizing SEM  (scanning electron microscopy) while the material was being characterized. In addition, the MTT assay and flow cytometry (Annexin V/PI staining) have been employed to assess cell viability at various times. A dialysis approach was used to investigate the drug release characteristics of DOX and Ezetimibe in films in vitro for 5 days. To optimize pharmacokinetic profiles and reduce systemic toxicity induced by drugs, we loaded polymeric PU-PCL films with ezetimibe (EZ) and doxorubicin (DOX). Co-delivery of EZ and DOX via film-carrier demonstrated improved anticancer effects when compared to free drug delivery. The co-delivery of DOX and EZ drugs by PU-PCL films improved anticancer effects while reducing systemic toxicity, suggesting clinical usage of drug-resistant prostate cancer therapy.